Recombinant human thrombopoietin clinical development.

D. V. Jones, M. Ashby, S. Vadhan-Raj, G. Somlo, R. Champlin, J. Gajewski, S. Hellmann, G. Fyfe

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Patients undergoing anticancer therapy are often at risk for developing severe and/or prolonged posttreatment thrombocytopenia. This can be associated with significant bleeding; currently, it is treated with supportive platelet transfusions. Frequent platelet transfusions can cause alloimmunization which requires HLA-matched donors and more frequent blood transfusions, and transmission of both viral and bacterial infections via platelet transfusions remains a concern. Furthermore, thrombocytopenia can mandate a decrease in the dose intensity of cytotoxic therapy by causing either delays or dose reductions in therapy administration. An intervention that reduces the risk or shortens the duration of severe thrombocytopenia would represent an important medical advance. Thrombopoietin (TPO), a naturally occurring, glycosylated polypeptide that was cloned by Genentech in 1994, is capable of inducing differentiation of stem cells into megakaryocytes and accelerating the maturation of megakaryocytes, thereby increasing the platelet count. Recombinant human TPO (rHuTPO) is currently undergoing testing in phase 1 and 2 studies in patients receiving myelosuppressive or myeloablative therapy. For the purposes of illustration, preliminary safety and activity data from one ongoing phase 1 myelosuppression trial (rHuTPO in women with advanced gynecologic malignancies receiving carboplatin) and one ongoing phase 1 myeloablation trial (rHuTPO for peripheral blood progenitor cell mobilization prior to myeloablative chemotherapy for high risk breast cancer) will be presented.

Original languageEnglish (US)
Pages (from-to)199-206
Number of pages8
JournalStem cells (Dayton, Ohio)
Volume16 Suppl 2
StatePublished - 1998
Externally publishedYes

Fingerprint

Thrombopoietin
Platelet Transfusion
Thrombocytopenia
Megakaryocytes
Stem Cells
Carboplatin
Virus Diseases
Therapeutics
Platelet Count
Bacterial Infections
Blood Transfusion
Blood Cells
Tissue Donors
Breast Neoplasms
Hemorrhage
Safety
Drug Therapy
Peptides
Neoplasms

ASJC Scopus subject areas

  • Cell Biology

Cite this

Jones, D. V., Ashby, M., Vadhan-Raj, S., Somlo, G., Champlin, R., Gajewski, J., ... Fyfe, G. (1998). Recombinant human thrombopoietin clinical development. Stem cells (Dayton, Ohio), 16 Suppl 2, 199-206.

Recombinant human thrombopoietin clinical development. / Jones, D. V.; Ashby, M.; Vadhan-Raj, S.; Somlo, G.; Champlin, R.; Gajewski, J.; Hellmann, S.; Fyfe, G.

In: Stem cells (Dayton, Ohio), Vol. 16 Suppl 2, 1998, p. 199-206.

Research output: Contribution to journalArticle

Jones, DV, Ashby, M, Vadhan-Raj, S, Somlo, G, Champlin, R, Gajewski, J, Hellmann, S & Fyfe, G 1998, 'Recombinant human thrombopoietin clinical development.', Stem cells (Dayton, Ohio), vol. 16 Suppl 2, pp. 199-206.
Jones DV, Ashby M, Vadhan-Raj S, Somlo G, Champlin R, Gajewski J et al. Recombinant human thrombopoietin clinical development. Stem cells (Dayton, Ohio). 1998;16 Suppl 2:199-206.
Jones, D. V. ; Ashby, M. ; Vadhan-Raj, S. ; Somlo, G. ; Champlin, R. ; Gajewski, J. ; Hellmann, S. ; Fyfe, G. / Recombinant human thrombopoietin clinical development. In: Stem cells (Dayton, Ohio). 1998 ; Vol. 16 Suppl 2. pp. 199-206.
@article{60c9c72d4d3b47f4af4c610f73f5c699,
title = "Recombinant human thrombopoietin clinical development.",
abstract = "Patients undergoing anticancer therapy are often at risk for developing severe and/or prolonged posttreatment thrombocytopenia. This can be associated with significant bleeding; currently, it is treated with supportive platelet transfusions. Frequent platelet transfusions can cause alloimmunization which requires HLA-matched donors and more frequent blood transfusions, and transmission of both viral and bacterial infections via platelet transfusions remains a concern. Furthermore, thrombocytopenia can mandate a decrease in the dose intensity of cytotoxic therapy by causing either delays or dose reductions in therapy administration. An intervention that reduces the risk or shortens the duration of severe thrombocytopenia would represent an important medical advance. Thrombopoietin (TPO), a naturally occurring, glycosylated polypeptide that was cloned by Genentech in 1994, is capable of inducing differentiation of stem cells into megakaryocytes and accelerating the maturation of megakaryocytes, thereby increasing the platelet count. Recombinant human TPO (rHuTPO) is currently undergoing testing in phase 1 and 2 studies in patients receiving myelosuppressive or myeloablative therapy. For the purposes of illustration, preliminary safety and activity data from one ongoing phase 1 myelosuppression trial (rHuTPO in women with advanced gynecologic malignancies receiving carboplatin) and one ongoing phase 1 myeloablation trial (rHuTPO for peripheral blood progenitor cell mobilization prior to myeloablative chemotherapy for high risk breast cancer) will be presented.",
author = "Jones, {D. V.} and M. Ashby and S. Vadhan-Raj and G. Somlo and R. Champlin and J. Gajewski and S. Hellmann and G. Fyfe",
year = "1998",
language = "English (US)",
volume = "16 Suppl 2",
pages = "199--206",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",

}

TY - JOUR

T1 - Recombinant human thrombopoietin clinical development.

AU - Jones, D. V.

AU - Ashby, M.

AU - Vadhan-Raj, S.

AU - Somlo, G.

AU - Champlin, R.

AU - Gajewski, J.

AU - Hellmann, S.

AU - Fyfe, G.

PY - 1998

Y1 - 1998

N2 - Patients undergoing anticancer therapy are often at risk for developing severe and/or prolonged posttreatment thrombocytopenia. This can be associated with significant bleeding; currently, it is treated with supportive platelet transfusions. Frequent platelet transfusions can cause alloimmunization which requires HLA-matched donors and more frequent blood transfusions, and transmission of both viral and bacterial infections via platelet transfusions remains a concern. Furthermore, thrombocytopenia can mandate a decrease in the dose intensity of cytotoxic therapy by causing either delays or dose reductions in therapy administration. An intervention that reduces the risk or shortens the duration of severe thrombocytopenia would represent an important medical advance. Thrombopoietin (TPO), a naturally occurring, glycosylated polypeptide that was cloned by Genentech in 1994, is capable of inducing differentiation of stem cells into megakaryocytes and accelerating the maturation of megakaryocytes, thereby increasing the platelet count. Recombinant human TPO (rHuTPO) is currently undergoing testing in phase 1 and 2 studies in patients receiving myelosuppressive or myeloablative therapy. For the purposes of illustration, preliminary safety and activity data from one ongoing phase 1 myelosuppression trial (rHuTPO in women with advanced gynecologic malignancies receiving carboplatin) and one ongoing phase 1 myeloablation trial (rHuTPO for peripheral blood progenitor cell mobilization prior to myeloablative chemotherapy for high risk breast cancer) will be presented.

AB - Patients undergoing anticancer therapy are often at risk for developing severe and/or prolonged posttreatment thrombocytopenia. This can be associated with significant bleeding; currently, it is treated with supportive platelet transfusions. Frequent platelet transfusions can cause alloimmunization which requires HLA-matched donors and more frequent blood transfusions, and transmission of both viral and bacterial infections via platelet transfusions remains a concern. Furthermore, thrombocytopenia can mandate a decrease in the dose intensity of cytotoxic therapy by causing either delays or dose reductions in therapy administration. An intervention that reduces the risk or shortens the duration of severe thrombocytopenia would represent an important medical advance. Thrombopoietin (TPO), a naturally occurring, glycosylated polypeptide that was cloned by Genentech in 1994, is capable of inducing differentiation of stem cells into megakaryocytes and accelerating the maturation of megakaryocytes, thereby increasing the platelet count. Recombinant human TPO (rHuTPO) is currently undergoing testing in phase 1 and 2 studies in patients receiving myelosuppressive or myeloablative therapy. For the purposes of illustration, preliminary safety and activity data from one ongoing phase 1 myelosuppression trial (rHuTPO in women with advanced gynecologic malignancies receiving carboplatin) and one ongoing phase 1 myeloablation trial (rHuTPO for peripheral blood progenitor cell mobilization prior to myeloablative chemotherapy for high risk breast cancer) will be presented.

UR - http://www.scopus.com/inward/record.url?scp=0032227912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032227912&partnerID=8YFLogxK

M3 - Article

C2 - 11012192

AN - SCOPUS:0032227912

VL - 16 Suppl 2

SP - 199

EP - 206

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

ER -